Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Talis Biomedical Corporation (TLIS : NSDQ)

• Company Description    Talis Biomedical Corporation engaged in developing and commercializing products for infectious diseases at the point-of-care. The company involved in developing the Talis One platform, a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform. Talis Biomedical Corporation is based in MENLO PARK, Calif. Number of Employees: 262

• Price / Volume Information    Yesterday's Closing Price: $1.02 Daily Weekly Monthly 20 Day Moving Average: 183,914 shares Shares Outstanding: 26.62 (millions) Market Capitalization: $27.15 (millions) Beta: 0.93 52 Week High: $12.88 52 Week Low: $0.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.27% 4.44% 12 Week -50.24% -45.30% Year To Date -74.56% -68.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 230 CONSTITUTION DRIVE - MENLO PARK,CA 94025 USA ph: 650-433-3000 fax: - ir@talisbio.com https://talisbio.com

• General Corporate Information    Officers Robert J. Kelley - Chief Executive Officer J. Roger Moody - Chief Financial Officer Felix Baker - Director Raymond Cheong - Director Melissa Gilliam - Director Peer Information Talis Biomedical Corporation (CORR.) Talis Biomedical Corporation (RSPI) Talis Biomedical Corporation (CGXP) Talis Biomedical Corporation (BGEN) Talis Biomedical Corporation (GTBP) Talis Biomedical Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87424L108 SIC: 3826 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 26.62 Most Recent Split Date: (:1) Beta: 0.93 Market Capitalization: $27.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.56 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 38.52% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.13 Price/Cash Flow: - Price / Sales: 6.20 EPS Growth vs. Year Ago Period: 72.89% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -54.47% vs. Previous Quarter: 271.45% ROE 03/31/22 - -66.55 12/31/21 - -67.21 09/30/21 - -103.75 ROA 03/31/22 - -55.84 12/31/21 - -56.83 09/30/21 - -64.65 Current Ratio 03/31/22 - 13.15 12/31/21 - 12.36 09/30/21 - 8.86 Quick Ratio 03/31/22 - 12.92 12/31/21 - 12.36 09/30/21 - 8.86 Operating Margin 03/31/22 - -3,757.88 12/31/21 - -2,343.90 09/30/21 - -2,742.84 Net Margin 03/31/22 - -3,757.88 12/31/21 - -2,343.90 09/30/21 - -2,742.84 Pre-Tax Margin 03/31/22 - -3,757.88 12/31/21 - -2,343.90 09/30/21 - -2,742.84 Book Value 03/31/22 - 7.62 12/31/21 - 8.90 09/30/21 - 10.07 Inventory Turnover 03/31/22 - 4.03 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©